TITLE

Laws fail to slow gray market

AUTHOR(S)
Lee, Jaimy
PUB. DATE
October 2011
SOURCE
Modern Healthcare;10/3/2011, Vol. 41 Issue 40, p14
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article expresses the concern of pharmacists and health providers regarding the short supply of drugs sold by secondary distributors. It says that there were 210 cases of drug shortages reported as of September 26, 2011 and that drugs purchased from the gray market were often priced 20 times higher than contracted drugs. It adds that the a Senate subcommittee urged the U.S. Food and Drug Administration (FDA) to establish a pedigree standard that would track drugs through the supply chain.
ACCESSION #
66631543

 

Related Articles

  • Move to allow purchase of Canadian drugs rejected.  // Modern Healthcare;10/24/2011, Vol. 41 Issue 43, p4 

    This article reports on the U.S. Senate's disapproval of an amendment to the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations bill.

  • Helping to shape drug shortage provisions in FDA user fee legislation. Keating, Armand // MLO: Medical Laboratory Observer;Oct2012, Vol. 44 Issue 10, p38 

    The article focuses on the U.S. FDA Safety and Innovation Act of 2012 which reauthorizes the FDA's user fee programs for five years and creating user fee programs for generic and biologic drugs. The law also addresses the problem of drug shortages which have had particularly devastating effects...

  • Drug shortages lead to action. Lee, Jaimy // Modern Healthcare;7/18/2011, Vol. 41 Issue 29, p16 

    The article reports on the impending drug shortage in the U.S., which prompted the American Hospital Association (AHA) to support legislation that would require the U.S. Food and Drug Administration to notify providers about drug shortages.

  • Patient Safeguards Needed for Biosimilar Development.  // Chicago Citizen - Chatham Southeast Edition;10/22/2014, Vol. 49 Issue 31, p16 

    The article focuses on the efforts of licensing for medications known as "biosimilars," similar to cutting-edge biologic medicines under the provision of the U.S. Patient Protection and Affordable Care Act. It mentions that the U.S. Food and Drug Administration (FDA), accepted the first...

  • Record high drug shortages warrant FDA policy changes, AHA tells House health panel.  // AHA News;7/11/2011, Vol. 47 Issue 14, p1 

    The article reports on the action of the U.S. Food and Drug Administration to avoid drug shortages, such as the implementation of the Prescription Drug User Fee Act and the Preserving Access to Life Saving Medications Act.

  • FDA May Alter Rules on Drug Combos.  // Chain Drug Review;9/27/2010, Vol. 32 Issue 16, p93 

    The article reports on the plan of the U.S. Food and Drug Administration (FDA) to change rules enabling manufacturers greater leeway in developing drug combinations.

  • FDA Actions.  // CenterWatch Monthly;Nov2015, Vol. 22 Issue 11, p16 

    A chart is presented depicting a sampling of the U.S. Food and Drug Administration (FDA) regulatory actions taken during October 2015.

  • AHA urges FDA to do more to end IV saline shortage.  // AHA News;3/21/2014, Vol. 50 Issue 6, p1 

    The article reports on the initiative of American Hospital Association (AHA) to motivate U.S. Food and Drug Administration (FDA) to provide actions concerning shortages of normal saline and other intravenous (IV) fluids in U.S. hospitals.

  • FDA is urged to speed up the rollout of proposed UDI system.  // AHA News;11/19/2012, Vol. 48 Issue 23, p3 

    The article reports on the move by the American Hospital Association (AHA) to appeal to the U.S. Food and Drug Administration (FDA) to expedite the implementation of the unique device identification (UDI) system within three years rather than the proposed seven years.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics